Immunic Inc Stock Price, News & Analysis

Immunic announced the closing of an oversubscribed $65 million public offering consisting of pre-funded warrants, series A warrants, and series B warrants to purchase common stock. The Pre-Funded Warrants are immediately exercisable, Series A Warrants are exercisable until December 31, 2025, and Series B Warrants will be exercisable from October 1, 2025, until June 3, 2030. The company could receive up to an additional $130 million if all warrants are exercised in full. The offering was co-led by BVF Partners and Coastlands Capital, with participation from notable institutional investors including Aberdeen Investments and Janus Henderson. Immunic plans to use the proceeds to fund clinical trials, operations, and general corporate purposes.

Immunic (NASDAQ: IMUX), a biotech company focused on developing oral small molecule therapies for inflammatory and autoimmune diseases, has announced its participation in several key conferences in June 2025. CEO Daniel Vitt will present a company overview at the Jefferies Healthcare Conference and attend multiple other events. The company will showcase data on their lead asset vidofludimus calcium (IMU-838) at scientific conferences, including antiviral applications at the RSC Anglo-Nordic Medicinal Chemistry Symposium and potential neuroprotective effects for multiple sclerosis at the European Academy of Neurology Congress. Management will also participate in partnering activities at the BIO International Convention and attend investor conferences including UBS Life Science Conference and ABI Conference 2025.

Immunic (NASDAQ: IMUX) has announced the pricing of an oversubscribed $65 million underwritten public offering consisting of pre-funded warrants, series A warrants, and series B warrants to purchase common stock. The combined public offering price is set at $0.7499 per unit. The company could receive up to an additional $130 million if all warrants are exercised in full for cash.

The pre-funded warrants will be immediately exercisable, Series A warrants will be exercisable until December 31, 2025, and Series B warrants will be exercisable from October 1, 2025, for five years. The offering is expected to close around June 3, 2025. Leerink Partners is acting as the sole bookrunner, with B. Riley Securities and Brookline Capital Markets as co-managers.

Immunic (NASDAQ: IMUX), a biotech company focused on developing oral therapies for chronic inflammatory and autoimmune diseases, has announced a new public offering. The offering includes pre-funded warrants to purchase common stock, along with two series of warrants: Series A warrants expiring December 31, 2025, and Series B warrants expiring five years after issuance.

Both Series A and B warrants will expire proportionally if the corresponding pre-funded warrant is exercised before September 30, 2025. Leerink Partners is serving as the sole bookrunner for the offering. The company plans to use the proceeds to fund clinical trials, operations, and general corporate purposes. The offering is being made through a shelf registration statement that became effective on May 31, 2024.

Immunic (NASDAQ: IMUX) has announced its participation in three major scientific and industry conferences in May 2025. At the Digestive Disease Week (DDW), two posters will present data on IMU-856, their SIRT6 modulator for celiac disease. At the Clinical Trial Supply Forum 2025 in Brussels, they will discuss supply chain challenges in the MENA region. At the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, the company will present preclinical data on vidofludimus calcium (IMU-838), their lead asset targeting Nurr1, potentially showing neuroprotective effects in multiple sclerosis.

Immunic announced positive results from its phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis patients. The drug showed a 20% reduction in disability worsening risk across all patients, with an impressive 30% reduction specifically in primary progressive multiple sclerosis (PPMS) patients.

Key findings include a 29% risk reduction in patients without gadolinium-enhancing lesions and a 20% decrease in thalamic brain volume loss compared to placebo. The trial involved 467 patients across North America and Europe, focusing on PPMS and non-active secondary progressive MS patients.

The drug demonstrated a favorable safety profile with no new safety concerns identified. Treatment-related adverse events were similar between drug (69.4%) and placebo (68.5%) groups. The company plans to present detailed results at upcoming scientific meetings, while phase 3 trials in relapsing multiple sclerosis continue with expected completion in 2026.

Immunic (Nasdaq: IMUX) has successfully closed its previously announced registered direct offering, raising $5.1 million in gross proceeds through the sale of 5,666,667 shares of common stock at $0.90 per share. The offering, which closed on April 10, 2025, was led by Aberdeen Investments.

The biotechnology company, focused on developing oral small molecule therapies for chronic inflammatory and autoimmune diseases, plans to utilize the net proceeds to fund clinical trials, operations, and other general corporate purposes. Titan Partners Group, a division of American Capital Partners, served as the sole placement agent for the offering.

Immunic (Nasdaq: IMUX) has announced the pricing of a $5.1 million registered direct offering of common stock, led by Aberdeen Investments. The company is offering 5,666,667 shares at $0.90 per share.

The biotechnology company, which develops oral small molecule therapies for chronic inflammatory and autoimmune diseases, expects to close the offering around April 10, 2025. The net proceeds will be used to fund clinical trials, operations, and general corporate purposes.

Titan Partners Group, a division of American Capital Partners, is serving as the sole placement agent for this offering, which is being conducted under a previously filed shelf registration statement that became effective on May 31, 2024.

Immunic (Nasdaq: IMUX), a biotechnology company focused on developing oral small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in two major conferences in April 2025.

The company will attend the American Academy of Neurology (AAN) 2025 Annual Meeting from April 5-9 in San Diego, California, where their team will be available at booth #2233.

Additionally, at the German Biotech Days 2025 (April 9-10) in Heidelberg, Chief Scientific Officer Hella Kohlhof, Ph.D., will present on their lead asset vidofludimus calcium (IMU-838), a nuclear receptor-related 1 (Nurr1) activator. The presentation titled 'Vidofludimus Calcium – Designed to Combine the Best of Two Worlds: Neuroprotection and Relapse Prevention' will discuss the company's journey from foundation to late-stage clinical trials.